Passive vaccination with a human monoclonal antibody: Generation of antibodies and studies for efficacy in bacillus anthracis infections

Immunobiology

Volumn 216, Issue 7, 2011, Pages 847-853

  vor dem Esche, Ulrich ^a   Huber, Maria ^a   Zgaga Griesz, Andrea ^a   Grunow, Roland ^b   Beyer, Wolfgang ^c   Hahn, Ulrike ^c   Bessler, Wolfgang G ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b BUNDESWEHR INSTITUTE OF MICROBIOLOGY   (Germany)

^c UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Anthrax toxins; Bacillus anthracis; CB F7 heteromyeloma cell line; Human monoclonal antibodies; Passive immunization

Indexed keywords

ANTHRAX VACCINE; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY HLF1; NEUTRALIZING ANTIBODY; PROTECTIVE ANTIGEN MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTHRAX; ANTIBODY PRODUCTION; ANTIGEN BINDING; ARTICLE; CANCER CELL CULTURE; CELL STRAIN CB F7; CONTROLLED STUDY; EPITOPE MAPPING; HUMAN; HUMAN CELL; IN VIVO STUDY; LETHAL GENE; MOLECULAR CLONING; MOUSE; NONHUMAN; PASSIVE IMMUNIZATION; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTHRAX; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; ANTIGENS, BACTERIAL; BACILLUS ANTHRACIS; BACTERIAL TOXINS; BACTERIAL VACCINES; CELL FUSION; CLONING, MOLECULAR; EPITOPE MAPPING; HUMANS; HYBRIDOMAS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; PEPTIDE FRAGMENTS; VACCINATION;

EID: 79957590835     PISSN: 01712985     EISSN: 18783279     Source Type: Journal    
DOI: 10.1016/j.imbio.2010.12.001     Document Type: Article

References (28)

1. Altboum Z., Gozes Y., Barnea A., Pass A., White M., Kobiler D. Post exposure prophylaxis against anthrax: evaluation of various treatment regimens in intranasally infected guinea pigs. Infect. Immun. 2002, 70(11):6231-6241.
2. Baier W., Heinevetter L., Huber M., Wiesmüller K.H., Jung G., Bessler W.G. The lipopeptide P3CSK4 constitutes an adjuvant in parenteral and oral immunization. Vaccine Res. 1997, 6:127-140.
3. Bhatnagar R., Batra S. Anthrax toxin. Crit. Rev. Microbiol. 2001, 27(3):167-200.
4. Bradley K.A., Mogridge J., Mourez M., Collier R.J., Young J.A. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414:225-229.
5. Cui X., Li Y., Moayeri M., Choi G.H., Subramanian G.M., Li X., Haley M., Fitz Y., Feng J., Banks S.M., Leppla S.H., Eichacker P.Q. Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis. J. Infect. Dis. 2005, 191(3):422-434.
6. Cullen B.R. Use of eukaryotic expression technology in the functional analysis of cloned genes. Methods Enzymol. 1987, 152:684-704.
7. Duesbery N.S., Webb C.P., Leppla S.H., Gordon V.M., Klimpel K.R., Copeland T.D., Ahn N.G., Oskarsson M.K., Fukasawa K., Paull K.D., Vande Woude G.F. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 1998, 280:734-737.
8. Friedlander A.M., Welkos S.L., Pitt M.L., Ezzell J.W., Worsham P.L., Rose K.J., Ivins B.E., Lowe J.R., Howe G.B., Mikesell P. Post exposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 1993, 167(5):1239-1243.
9. Garmory H.S., Titball R.W., Griffin K.F., Hahn U., Böhm R., Beyer W. Salmonella enterica Serovar Typhimurium expressing a chromosomally integrated copy of the Bacillus anthracis protective antigen gene protects mice against an anthrax spore challenge. Infect. Immun. 2003, 71(7):3831-3836.
10. Grunow R., Porsch-Özcürümez M., Splettstösser W., Beckendahl A., Hahn U., Beyer W., Böhm R., Huber M., Esche U.V.D., Bessler W., Frangoulidis D., Finke E.J. Monitoring of ELISA-reactive antibodies against anthrax protective antigen (PA), lethal factor (LF), and toxin-neutralising antibodies in serum of individuals vaccinated against anthrax with the PA-based UK anthrax vaccine. Vaccine 2007, 25:3679-3683.
11. Hahn U.K., Alex M., Czerny C.P., Böhm R., Beyer W. Protection of mice against challenge with Bacillus anthracis STI spores after DNA vaccination. Int. J. Med. Microbiol. 2004, 294(1):35-44.
12. Hoffmann P., Jimenez-Diaz M., Loleit M., Jung G., Grimm R., Schäfer E., Bessler W.G. Antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations and for the preparation of human and murine monoclonal antibodies. Immunobiology 1990, 181:211.
13. Hoffmann P., Jimenez-Diaz M., Loleit M., Tröger W., Wiesmüller K.-H., Metzger J., Jung G., Kaiser I., Stöcklin S., Lenzner S., Peters J.H., Grimm R., Schäfer E., Bessler W.G. Preparation of human and murine monoclonal antibodies: antigens combined with or conjugated to lipopeptides constitute potent immunogens for in vitro and in vivo immunizations. Hum. Antibod. Hybridomas 1990, 1(3):137-144.
14. Hoffmann P., Jimenez-Diaz M., Weckesser J., Bessler W.G. Murine bone marrow-derived macrophages constitute feeder cells for human B cell hybridomas. J. Immunol. Methods 1996, 196:85-91.
15. Jones W.I., Klein F., Lincoln R.E., Walker J.S., Mahlandt B.G., Dobbs J.P. Antibiotic treatment of anthrax infection in mice. J. Bacteriol. 1967, 94(3):609-614.
16. Kumar P., Ahuja N., Bhatnagar R. Anthrax edema toxin requires influx of calcium for inducing cyclic AMP toxicity in target cells. Infect. Immun. 2002, 70(9):4997-5007.
17. Lim N.K., Kim J.H., Oh M.S., Lee S., Kim S.Y., Kim K.S., Kang H.J., Hong H.J., Inn K.S. An anthrax lethal factor-neutralizing monoclonal antibody protects rats before and after challenge with anthrax toxin. Infect. Immun. 2005, 73(10):6547-6555.
18. Maldonado-Arocho F.J., Averette-Mirrashidi K.M., Bradley K.A. Microbial Toxins: Current Research and Future Trends 2009, Caister Academic Press.
19. Maynard J.A., Maassen C.B., Leppla S.H., Brasky K., Patterson J.L., Iverson B.L., Georgiou G. Protection against anthrax toxin by recombinant antibody fragments correlates with antigen affinity. Nat. Biotechnol. 2002, 20(6):597-601.
20. Mohamed N., Li J., Ferreira C.S., Little S.F., Friedlander A.M., Spitalny G.L., Casey L.S. Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages. Infect. Immun. 2004, 72:3276-3283.
21. Pannifer A.D., Wong T.Y., Schwarzenbacher R., Renatus M., Petosa C., Bienkowska J., Lacy D.B., Collier R.J., Park S., Leppla S.H., Hanna P., Liddington R.C. Crystal structure of the anthrax lethal factor. Nature 2001, 414:229-233.
22. Park J.M., Greten F.R., Li Z.W., Karin M. Macrophage apoptosis by anthrax lethal factor through p38 MAP kinase inhibition. Science 2002, 297(5589):2048-2051.
23. Robertson D.L., Tippetts M.T., Leppla S.H. Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase. Gene 1988, 73(2):363-371.
24. Grunow R., Jahn S., Porstmann T., Kiessig S., Steinkellner H., Steindl F., Mattanovich D., Guertler L., Deinhardt F., Katinger H., Von Baehr R. The high efficiency, human B cell immortalizing heteromyeloma CB-F7. J. Immunol. Methods 1988, 106:257-265.
25. Ross J.M. The pathogenesis of anthrax following the administration of spores by respiratory route. J. Pathol. Bacteriol. 1957, 73:483-486.
26. Sawada-Hirai R., Jiang I., Wang F., Sun S.M., Nedellec R., Ruther P., Alvarez A., Millis D., Morrow P.R., Kang A.S. Human anti-anthrax protective antigen neutralizing monoclonal antibodies derived from donors vaccinated with anthrax vaccine adsorbed. J. Immune Based Ther. Vaccines 2004, 2(1):5.
27. Takekoshi M., Maeda F., Tachibana H., Inoko H., Kato S., Takakura I., Kenjyo T., Hiraga S., Ogawa Y., Horiki T., Ihara S. Human monoclonal anti-HCMV neutralizing antibody from phage display libraries. J. Virol. Methods 1998, 74(1):89-98.
28. Zhao P., Liang X., Kalbfleisch J., Koo H.M., Cao B. Neutralizing monoclonal antibody against anthrax lethal factor inhibits intoxication in a mouse model. Hum. Antibodies 2003, 12(4):129-135.